ClinicalTrials.Veeva

Menu

Exercise as a Tool to Improve Response to Immunotherapy in Non-small Cell Lung Cancer (ImmuEX)

M

Medical University of Graz

Status

Not yet enrolling

Conditions

Exercise Training
Immunotherapy
Non-Small Cell Lung Cancer

Treatments

Other: Control
Behavioral: Exercise

Study type

Interventional

Funder types

Other

Identifiers

NCT07267000
ImmuEX
PAT1625724 (Other Identifier)

Details and patient eligibility

About

This project is about the effect of a 12-week training therapy intervention in patients suffering from non-small cell lung cancer. It has widely been accepted that exercise is preventive against certain types of cancer. Individuals following an active lifestyle have a significantly lower risk for several chronic diseases, including cancer, as compared to sedentary ones. However, evidence is still lacking for exercise as part of routine cancer treatment (as it has already been implemented routinely in patients with heart disease, for example). In this study, patients suffering from non-small cell lung cancer undergo either a 12-week training program consisting of moderate-intensity continuous exercise (MICE), or a 12-week program with high-intensity interval exercise. Both groups will be compared to a control group receiving standard exercise recommendations. The response to immunotherapy, measured by the radiologic therapy response, will be the main endpoint. Additionally, blood will be taken from the patients at different timepoints, and blood samples will be tested for immunologic changes. FACS analysis will be used to assess the properties of immune cells and potential changes upon the exercise regimen. Mitochondrial function will be assessed via the Seahorse machine, and mass spectrometry (lipidomics) will be used for the analysis of lipid profile changes.

Full description

Lung cancer is the number one cause of cancer-related deaths worldwide. A few decades ago, the prognosis at lung cancer first diagnosis was generally poor with only a few months of median survival. New immunotherapy treatment regimens have markedly improved survival times - especially in certain histologic and molecular pathologic subtypes. The positive effect of exercise on the incidence of several cancer entities such as colorectal- or breast cancer, has been demonstrated previously. Physically active individuals are diagnosed with cancer significantly less often as compared to sedentary people. In oncologic follow-up care, a positive effect of exercise and training with an advantage in survival has also been proven, e.g. in breast cancer patients.

In addition, existing data shows a positive effect of exercise on the immune system: active individuals show a different pattern of proinflammatory markers in the blood serum, with every exercise session generating an immune-stimulatory effect which changes the immunologic serum profile also at rest. Thus, regular exercise has an anti-inflammatory long-term effect.

Hypothesis and Objectives: With our project we seek to demonstrate a possible benefit on immunotherapy response upon a medically guided training regimen.

Setting and Methods. To exactly define "exercise" in this setting, as a first step we will test two exercise types in healthy individuals. According to their individual exercise capacity as determined by spiroergometry, healthy subjects will either perform moderate-intensity continuous exercise (MICE), or a high-intensity interval training (HIIT). By means of venous blood sampling before and after training we shall determine the respective changes of serum immune markers through exercise. The same two training types will then be performed by lung cancer patients upon immunotherapy, with one patient group doing MICE-sessions, one group doing the HIIT and a third group who will receive general exercise recommendations. Response to therapy and inflammatory serum parameters will be compared between the groups. Exercising patients will be advised to train once a week under medical supervision, and to walk briskly for 30 minutes every day of the week in addition. Our hypothesis is, that exercise should be implemented as a complementary treatment strategy in every oncologic therapy setting, possibly improving not only physical health and wellbeing but also treatment response. In addition to improving the patients' quality of life by a better physical capacity and fitness, helping them in their everyday activities, we propose that the implementation of exercise programs in various oncologic settings in future may improve the patients' outcome.

Scientific Novelty. Standardization of exercise regimens in oncologic scenarios in the existing literature is generally poor. We carry out one of the few studies where the type, duration, timing and intensity of exercise in both exercise groups is clearly defined, comparing two different training types to sedentary control patients, respectively. Exercise needs to be seen as a drug, and like in any drug the optimum dose must be clearly outlined. Moreover, we will implement a priming exercise in our study, meaning that patients exercise close to the administration of immunotherapy, hypothesizing that this may further ameliorate therapy response.

Enrollment

100 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria: Patients suffering from non-small cell lung cancer of any histologic subtype at first diagnosis, receiving a treatment regimen comprising immunotherapy (with or without chemotherapy).

-

Exclusion Criteria:

  • Kachexia (BMI<18.5)
  • instable bone metastases
  • orthopedic condition rendering the patient unable to ride a stationary bike
  • any medical contraindication for exercise and training

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

100 participants in 3 patient groups

Continuous Exercise
Experimental group
Description:
Patients in this arm will undergo a 12-week training therapy regimen consisting of twice weekly supervised moderate-intensity continuous exercise (MICE) and home-based walking exercise for 30 minutes, five times a week, in addition.
Treatment:
Behavioral: Exercise
High Intensity Interval Exercise
Experimental group
Description:
Patients in this arm will undergo a 12-week training therapy regimen consisting of twice weekly supervised high-intensity interval exercise and home-based walking exercise for 30 minutes, five times a week, in addition.
Treatment:
Behavioral: Exercise
Controls
Active Comparator group
Description:
Patients in this arm will receive general recommendations on an active lifestyle, but will not take part in supervised training sessions and are not asked to do home-based exercise either.
Treatment:
Other: Control

Trial contacts and locations

1

Loading...

Central trial contact

Peter Hofmann, Prof. Mag. Dr.; Elisabeth Taucher, Dr. Dr.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems